CJC-1295 No DAC (Modified GRF 1-29) is a synthetic growth hormone-releasing hormone analog composed of 29 amino acids designed to stimulate natural growth hormone production. Research demonstrates CJC-1295 No DAC significantly increases growth hormone and IGF-1 levels through pulsatile release that mimics natural physiological patterns. Studies show administration of GHRH analogs increases lean body mass, reduces visceral fat accumulation, improves muscle strength, and enhances recovery. The peptide activates GHRH receptors in the anterior pituitary to promote endogenous growth hormone secretion without suppressing natural production. Clinical trials indicate GHRH treatment improves body composition, increases bone mineral density, enhances sleep quality, and supports tissue repair mechanisms through sustained IGF-1 elevation.

CJC-1295 with DAC is a synthetic growth hormone-releasing hormone (GHRH) analog engineered with a Drug Affinity Complex for extended biological activity. Clinical studies demonstrate CJC-1295 increases plasma growth hormone levels 2- to 10-fold for 6+ days and IGF-1 levels 1.5- to 3-fold for 9-11 days from a single dose. Research shows the peptide normalizes body composition by maintaining lean muscle mass while reducing subcutaneous fat accumulation. Studies indicate CJC-1295 preserves pulsatile GH secretion while markedly increasing trough GH levels by 7.5-fold, supporting muscle protein synthesis, collagen formation, and bone matrix deposition. The peptide demonstrates efficacy in promoting osteoblast activity, enhancing tissue repair, and improving metabolic parameters including insulin sensitivity and lipolysis.

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide neuropeptide first discovered in 1974, composed of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu). Research demonstrates DSIP significantly enhances sleep quality, particularly slow-wave deep sleep, while reducing sleep latency without sedative effects. Studies show DSIP modulates the hypothalamic-pituitary-adrenal axis, reducing cortisol and stress responses. Clinical trials demonstrate remarkable efficacy in treating withdrawal symptoms, with 97% of opiate-dependent and 87% of alcohol-dependent patients experiencing symptom relief. DSIP exhibits analgesic properties for chronic pain conditions, neuroprotective effects through antioxidant mechanisms, and geroprotective actions including 2.6-fold reduction in spontaneous tumor incidence in long-term studies.

 

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a natural pineal gland extract. Research demonstrates Epithalon significantly extends telomere length through telomerase activation in human somatic cells, with studies showing cellular lifespan extension beyond the Hayflick limit. In animal models, Epithalon increased maximum lifespan by 12-13% and reduced mortality rates by up to 52% in human clinical trials. The peptide restores circadian rhythm by enhancing melatonin production in aged subjects, improves immune function through increased T-lymphocyte proliferation, and provides potent antioxidant protection by elevating superoxide dismutase and glutathione peroxidase activity. Clinical studies show 90% efficacy in treating retinitis pigmentosa and significant reductions in chromosomal aberrations.

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) first isolated from human plasma in 1973. This bioactive peptide demonstrates remarkable tissue regenerative properties, enhancing wound healing, collagen synthesis, and cellular repair mechanisms. Research shows GHK-Cu modulates expression of over 30% of human genes, promoting tissue remodeling while suppressing inflammatory pathways. The peptide increases collagen production by up to 70%, accelerates wound healing by 30-50%, and reduces wrinkle depth by 33%. GHK-Cu levels decline from 200 ng/mL at age 20 to 80 ng/mL by age 60, correlating with decreased regenerative capacity. Studies demonstrate improvements in skin density, hair follicle enlargement, and DNA repair gene activation, making it valuable for anti-aging applications and tissue restoration.

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that acts as a potent growth hormone secretagogue, stimulating pulsatile GH release from the pituitary gland through ghrelin receptor activation. Research demonstrates GHRP-2 significantly elevates growth hormone and IGF-1 levels, enhancing lean muscle mass, promoting fat metabolism, and supporting tissue repair. Clinical studies show GHRP-2 administration increases GH secretion more effectively than GHRH alone, with sustained effects over extended treatment periods. The peptide exhibits cardioprotective properties, reduces inflammation, improves sleep quality, and supports bone density maintenance. GHRP-2 enhances exercise recovery, accelerates wound healing, and demonstrates synergistic effects when combined with GHRH analogs, making it valuable for muscle building, metabolic optimization, and age-related hormone decline.